Bellevue Group AG Has $3.78 Million Stock Holdings in 10x Genomics $TXG

Bellevue Group AG lifted its stake in 10x Genomics (NASDAQ:TXG) by 41.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 326,751 shares of the company’s stock after acquiring an additional 95,754 shares during the quarter. Bellevue Group AG’s holdings in 10x Genomics were worth $3,784,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of TXG. Bank of America Corp DE boosted its position in 10x Genomics by 13.4% during the second quarter. Bank of America Corp DE now owns 3,023,489 shares of the company’s stock valued at $35,012,000 after purchasing an additional 356,100 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of 10x Genomics by 239.8% during the 2nd quarter. Ameriprise Financial Inc. now owns 443,749 shares of the company’s stock worth $5,139,000 after purchasing an additional 313,160 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of 10x Genomics by 241.3% during the 2nd quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company’s stock worth $47,916,000 after purchasing an additional 2,925,372 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in shares of 10x Genomics in the 2nd quarter valued at approximately $1,355,000. Finally, Quantinno Capital Management LP boosted its holdings in shares of 10x Genomics by 207.2% in the 2nd quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company’s stock valued at $25,864,000 after buying an additional 1,506,530 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Insider Buying and Selling

In other 10x Genomics news, insider Benjamin J. Hindson sold 8,283 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $157,377.00. Following the transaction, the insider owned 432,605 shares in the company, valued at $8,219,495. This trade represents a 1.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Taich sold 11,888 shares of 10x Genomics stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $225,872.00. Following the sale, the chief financial officer directly owned 297,385 shares of the company’s stock, valued at $5,650,315. This represents a 3.84% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 33,432 shares of company stock valued at $635,208. Insiders own 9.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TXG. Canaccord Genuity Group boosted their target price on shares of 10x Genomics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Zacks Research lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. JPMorgan Chase & Co. upped their target price on shares of 10x Genomics from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Piper Sandler lifted their price target on 10x Genomics from $15.00 to $19.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $20.00 price target (up previously from $17.00) on shares of 10x Genomics in a research report on Monday, December 1st. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $15.35.

10x Genomics Stock Performance

Shares of TXG opened at $15.46 on Friday. The firm has a market cap of $1.96 billion, a P/E ratio of -24.94 and a beta of 2.15. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $20.34. The firm’s 50-day simple moving average is $15.07 and its 200 day simple moving average is $13.26.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.The company had revenue of $149.00 million during the quarter, compared to analysts’ expectations of $142.50 million. During the same quarter in the previous year, the company posted ($0.30) earnings per share. The business’s revenue was down 1.7% on a year-over-year basis. As a group, equities analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.